Strong Revenue Growth Boosts Alnylam Pharmaceuticals Stock
Recently, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) saw its stock surge by 5.5%. This uplifting moment came after the company disclosed its preliminary revenue figures for the fourth quarter and full year 2024. These numbers surpassed market expectations and hinted at a bright financial outlook for 2025, steering the company toward potential non-GAAP profitability.
Impressive Revenue Figures for 2024
The company, recognized as a leader in RNAi therapeutics, reported impressive global net product revenues for its existing products, including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. Alnylam achieved over $1.6 billion in net product revenues for 2024, marking a significant growth of 33% compared to the previous year. This stellar performance underscores the strength of its hATTR-PN and Rare Disease businesses.
Future Projections and Launch Expectations
As Alnylam looks towards 2025, the company identifies this year as pivotal. The anticipated launch of vutrisiran in ATTR-CM is expected to be a key contributor to substantial revenue growth. The guidance for combined net product revenues in 2025 ranges from $2,050 million to $2,250 million, indicating a 31% increase at the midpoint over 2024. A breakdown shows projected revenues of $1,600 million to $1,725 million for their Total TTR franchise, reflecting a robust 36% growth, alongside $450 million to $525 million for their Total Rare franchise, which would signify a 15% increase.
CEO Insights and Market Confidence
Alnylam’s CEO, Yvonne Greenstreet, expressed confidence in the company’s forward momentum, claiming that 2025 could be an inflection point for their TTR franchise. She articulated optimism regarding the potential effects of vutrisiran's launch on overall sales, suggesting that achieving the revenue guidance could lead Alnylam towards non-GAAP profitability by 2025.
Analyst Perspectives on Product Performance
Analyst Ritu Baral from TD Cowen remarked on the company's strong performance and robust future projections. The revenues from ONPATTRO and AMVUTTRA for the fourth quarter and full fiscal year exceeded expectations, signaling strong market demand. Though GIVLAARI’s revenues slightly missed consensus expectations, the overall trend remains positive. Baral highlighted that all eyes are on the looming PDUFA date set for March 23, 2025, which concerns the FDA’s approval of vutrisiran for treating adults suffering from ATTR amyloidosis with cardiomyopathy.
Looking Ahead
Investors remain vigilant as Alnylam gears up for further discussions concerning their preliminary 2024 product revenues and their ambitious goals for 2025. These discussions are anticipated to take place during a webcast presentation at the 43rd Annual J.P. Morgan Healthcare Conference. Furthermore, the company forecasts additional global approvals and reimbursement paths in Japan and the EU for vutrisiran in the latter half of 2025.
Frequently Asked Questions
What is driving Alnylam's stock surge?
The surge is attributed to the company’s exceeding market expectations in their revenue forecasts and optimistic guidance for 2025.
What revenue growth did Alnylam achieve in 2024?
Alnylam reported over $1.6 billion in net product revenues in 2024, marking a 33% increase from the previous year.
What are the expectations for Alnylam in 2025?
Alnylam aims to achieve non-GAAP profitability in 2025, driven by the anticipated launch of vutrisiran and strong performance in its product lines.
What did analysts say about Alnylam's performance?
Analysts indicated strong market demand for Alnylam's products, highlighting their performance against consensus expectations.
What is the significance of the March 23 PDUFA date?
This date is crucial for the FDA's review and potential approval of vutrisiran, which could significantly impact Alnylam's revenue trajectory.
